A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma
Latest Information Update: 22 Jun 2024
At a glance
- Drugs XmAb 819 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Xencor
- 27 Feb 2024 According to a Xencor media release, plans to advance the ongoing Phase 1 dose-escalation study toward target dose levels in 2024.
- 26 Sep 2023 Planned End Date changed from 1 Apr 2026 to 1 Mar 2027.
- 09 Jan 2023 According to Xencor media release, the company intends to continue the enrollment of patients in this study.